Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de OBIZUR en adultos con hemofilia A adquirida (AHA) en Corea del Sur

4 de noviembre de 2026 actualizado por: Takeda

Vigilancia poscomercialización (vigilancia de uso-resultado) de la inyección de OBIZUR [Susoctocog Alpha (factor VIII antihemofílico porcino, recombinante)] para las indicaciones aprobadas en Corea del Sur

Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.

The main aim of the study is to learn how safe OBIZUR is in adults with AHA.

Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.

The treatment of the participants will be determined by the treating physicians.

During the study, data already existing in the participants' medical record and new data will be collected.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.

Tipo de estudio

De observación

Inscripción (Estimado)

11

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Takeda Contact
  • Número de teléfono: +1-877-825-3327
  • Correo electrónico: medinfoUS@takeda.com

Ubicaciones de estudio

      • Seoul, Corea del Sur, 06591
        • Reclutamiento
        • The Catholic University of Korea, Seoul St. Mary's Hospital
        • Contacto:
        • Investigador principal:
          • Jae-ho Yoon
      • Seoul, Corea del Sur, 05278
        • Reclutamiento
        • Kyung Hee University Hospital at Gangdong
        • Contacto:
        • Investigador principal:
          • Young Shil Park, Ph.D
      • Seoul, Corea del Sur, 07804
        • Reclutamiento
        • Ewha Womans University Medical Center
        • Contacto:
          • Site Contact
          • Número de teléfono: +82-2-6986-3100
          • Correo electrónico: anemia@khu.ac.kr
        • Investigador principal:
          • Jae-joon Han
      • Ulsan, Corea del Sur, 44033
        • Reclutamiento
        • Ulsan University Hospital
        • Investigador principal:
          • Yoo Jin Lee
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Participants with AHA who are receiving OBIZUR Injection or initiate OBIZUR Injection treatment for the first time will be enrolled.

Descripción

Inclusion Criteria:

  • Participants with AHA.
  • Participants who are determined to have the clinical need to receive Obizur treatment.
  • Participants aged 18 years or older at time of initiation of Obizur treatment.
  • Participants agreed to participate in the study and voluntarily signed the informed consent.

Exclusion Criteria:

  • Participants with hypersensitivity to any of the components of this drug.
  • Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
  • Participants for whom Obizur treatment is contraindicated as per product label.
  • Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: OTHER

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
All Participants

Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice.

OBIZUR injection.

Otros nombres:
  • TAK-672
  • Susoctocog Alfa
  • Factor VIII antihemofílico porcino, recombinante

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI)
Periodo de tiempo: Up to 3 months

Number of participants with AEs, causality to AEs, SAEs and AESI will be reported. The investigator will assess the causal relationship (causality) between the medicinal product and the AE using his/her clinical expertise and judgment.

Up to 3 months
Number of Participants With Expected/Unexpected AEs and SAEs
Periodo de tiempo: Up to 3 months

Unexpected AE is defined as AE that differs from the information in the product label in nature, severity, specificity, or outcome.

Up to 3 months
Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRs
Periodo de tiempo: Up to 3 months

An ADR refers to any undesirable and unintended reaction which occurs during or following the administration of the drug, and in which a causal relationship with the drug cannot be ruled out. In the event that a causal relationship with the drug remains unknown amongst reported adverse events, such reaction shall be considered an adverse drug reaction. Serious ADR means noxious or unintended response to a drug that occurs at any dosage and that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death. Unexpected ADRs is defined as ADR that differs from the information in the product label in nature, severity, specificity, or outcome.

Up to 3 months
Number of Participants With Special Situation Report (SSR)
Periodo de tiempo: Up to 3 months

SSR include following events: Pregnancy: any case in which a pregnancy participant is exposed to a Takeda Product or in which a female participant or partner of a male participant becomes pregnant following Takeda product.; Breastfeeding: infant exposure from breast milk; Overdose: all information of any accidental or intentional overdose; Drug abuse, misuse or medication error: all information on medicinal product (MP) abuse, misuse of medication error (potential or actual); Suspected transmission of infectious agent: Suspected (in sense of confirmed or potential) transmission of infectious agent by a MP; Lack of efficacy of Takeda Product; accidental/occupational exposure; Use outside the terms of the marketing authorization, also known as "off-label" and "off-label use"; Use of falsified and counterfeit MP; Drug-drug and drug-food interactions; Inadvertent or accidental exposure with or without an AE; Unintended benefit.

Up to 3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Overall Bleeding Control
Periodo de tiempo: Up to 3 months

Overall Bleeding Control will be determined as either bleeding stopped or did not stop.

Up to 3 months
Time to Achieve Bleeding Control With OBIZUR Injection
Periodo de tiempo: Up to 3 months

Time to achieve bleeding control will be assessed from initiation of OBIZUR Injection (start time) to the time to achieve bleeding control (stop time).

Up to 3 months
Number of OBIZUR Injection Infusion Required to Achieve Bleeding Control
Periodo de tiempo: Up to 3 months

Number of OBIZUR injection infusion required to achieve bleeding control will be reported.

Up to 3 months
Dose of OBIZUR Required to Stop the Bleeding
Periodo de tiempo: Up to 3 months

OBIZUR dose required to stop the bleeding will be reported.

Up to 3 months
Percentage of Participants With Bleeding Events
Periodo de tiempo: Up to 3 months

Bleeding events will be evaluated and reported as re-bleed, concurrent bleed and subsequent bleed. Re-bleed: if it occurs in the same anatomical location and within 72 hours of the resolution of the previous bleeding. Concurrent bleed: if it occurs at the same time (that is, during treatment or within 72 hours of resolution) as previous bleed but at a different anatomical location. Subsequent bleed: if it is a new bleed occurring 72 hours after the resolution of the previous bleed (either in the same anatomical location or in a new one).

Up to 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Study Director, Takeda

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de julio de 2025

Finalización primaria (Estimado)

31 de diciembre de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

9 de agosto de 2024

Primero enviado que cumplió con los criterios de control de calidad

9 de agosto de 2024

Publicado por primera vez (Actual)

13 de agosto de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criterios de acceso compartido de IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir